Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Ind-Swift Laboratories Limited

NSE: INDSWFTLABPharmaceuticalsASM stage 1

Share price

₹360.90

-1.42% close of 9 Oct 2026

Market cap ₹3,140 CrP/E 48.3

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

44

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹3,140 Cr

P/E ratio

48.3

P/B ratio

2.3

ROCE

4.9%

ROE

4.0%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹413.1052-week low ₹88.15

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Our sales figures for this company step down at Jun 2024 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.

Whether it grew faster than its sector

Our sales figures for this company step down at Jun 2024 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.

Room to re-rate, or risk of de-rating

At 48.3× earnings it costs 2.0× the market, which pays 24.1× across 2199 companies we can price. Its own industry sits at 79.4×, across 5 companies. It is against its own five-year median of 13.6×, the 96th percentile of its own range.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

Profit growthPrice per ₹1 profitPer 1% growth
Ind-Swift Laboratories Limited — this one-6%/yr48.3×—
Divi's Laboratories13%/yr83.1×₹6.4
Torrent Pharmaceuticals22%/yr79.4×₹3.6
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1
Cipla10%/yr29.4×₹2.9

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 103 of 130 on returns, 110 of 127 on growth, 108 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 4.9% on capital, ahead of 21% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹85 crore of cash from the business but spent ₹181 crore on plant and equipment, ₹96 crore more than it made; the gap was from shareholders — borrowings did not rise. And the profit is real: of every 100 rupees it reported over 12 years, about 110 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 253 days for its cash to waiting 156 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 10 checks clear · 70%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 25% year on year and profit nearly tripled as export-led margins expanded.

Announced 10 Aug 2026 · Consolidated · Unaudited

Revenue

₹191 Cr

Revenue vs last year

+25.1%

Revenue vs last quarter

+12.6%

Net profit

₹25 Cr

Profit vs last year

+174.3%

Profit vs last quarter

+64.6%

Net margin

12.9%

EPS

₹2.84

Earnings call transcript · 17 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹3,140 Cr
Prev close
₹360.90
52w High
₹425
52w Low
₹87.2
Enterprise value
₹2,716 Cr
Beta
0.7
Price CAGR 1y
285.0%
Price CAGR 3y
63.0%
Price CAGR 5y
44.0%
Price CAGR 10y
25.0%

Ratios

Return on assets
2.6%
PEG ratio
-8.0
P/E ratio
48.3
P/B ratio
2.3
EV / EBITDA
46.0
Industry P/E
37.6
ROCE
4.9%
ROCE 5y average
9.6%
ROE
4.0%
Debt / Equity
0.0
Interest coverage
52.0
Dividend yield
0.0%
ROE 3y average
7.0%
ROE last year
4.0%

Annual P&L

Annual revenue
₹649 Cr
Annual profit
₹43 Cr
Operating margin
7.0%
Net profit margin
6.6%
EBITDA margin
7.2%
Sales growth 3y
-18.7%
Sales growth 5y
-6.1%
Profit growth 3y
-6.0%
Profit growth 5y
79.0%
EPS
₹5.0
Sales growth TTM
54.0%
Profit growth TTM
195.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹191 Cr
Profit latest quarter
₹25 Cr
YoY quarterly sales growth
25.4%
YoY quarterly profit growth
177.8%
OPM latest quarter
17.5%

Balance Sheet

Book Value
₹159
Face Value
₹10.0
Total debt
₹18 Cr
Total cash
₹430 Cr
Borrowings
₹18 Cr
Reserves / Equity
14.9

Cash Flow

Operating cash flow
-₹68 Cr
Free cash flow
-₹155 Cr
FCF yield
-5.0%
Net cash flow
₹5 Cr

Shareholding

Promoter holding
42.9%
FII holding
10.9%
DII holding
0.1%
Public holding
46.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Ind-Swift Labs.391.1052.33,4010.0024.7183.5191.525.44.9
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales3102902885293312129138153153151170191
Expenses2502242364374324135147149151147149158
Material Cost65666682
Change in Inventories-0.97-0.35-5.64-17
Purchases of Stock-in-Trade8.66129.8514
Employee Cost33363240
Other Expenses44374440
Operating Profit60665291-10-12-7-94142133
OPM %19231817-29-99-5.16-6.662.360.962.761217
Other Income677458111316220151822-37
Exceptional items (within Other Income)21600-5.85-5.15-0.24
Interest20212130010-27121-21
Depreciation14131420006777988
Profit before tax32392452711-72301010161233
Tax %4518196-331-164172242-2625
Net Profit17321949410-522298101525
EPS in Rs2.925.363.29840.160.07-0.93371.450.981.171.742.84
Diluted EPS in Rs301.170.961.131.762.84

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6606537167657577808911,0391,2071,281574649665
Expenses5715466106316306357098379781,029581602605
Material Cost224272
Change in Inventories-7.05-27
Purchases of Stock-in-Trade7138
Employee Cost118138
Other Expenses176176
Operating Profit89107106134126144183202229252-74760
OPM %13161518171921191920-1.2079
Other Income-311151612033233774342923644
Exceptional items (within Other Income)223-11
Interest1171068828921071009692512.9211
Depreciation8485888710490871315753243132
Profit before tax-143-83-553650-201813875822585171
Tax %-17-29-29394271171174528315
Net Profit-119-59-392229-21-3-2484212504357
EPS in Rs-29-14-8.754.856.09-3.59-0.53-0.368.0671414.976.73
Diluted EPS in Rs354.84
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
-0%
5 years
-6%
3 years
-19%
TTM
54%

Compounded profit growth

10 years
12%
5 years
79%
3 years
-6%
TTM
195%

Stock price CAGR

10 years
25%
5 years
44%
3 years
63%
1 year
285%

Return on equity

10 years
3%
5 years
6%
3 years
7%
Last year
4%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital424245464860606060596987
Reserves5534764865075405815445416228721,1041,297
Borrowings1,4131,4571,2421,0831,1481,0311,005953862173318
Other Liabilities236240364387188198210247280217232271
Minority Interest-0.03-0.06
Total Liabilities2,2442,2152,1382,0231,9241,8701,8181,8011,8241,1651,4381,673
Fixed Assets1,1171,0991,0429349148437536305878273304
CWIP1137870692011191080012
Investments181818181917362930111213248
Other Assets9971,0201,0071,0029729981,0111,1311,1991,0479521,110
Total Assets2,2442,2152,1382,0231,9241,8701,8181,8011,8241,1651,4381,673

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity98799673-64125135150195-163-29-68
Cash from Investing Activity-35-29-31-17-12-9-105-13-104-113-69
Cash from Financing Activity-64-48-69-62100-133-124-141-18669972142
Net Cash Flow-13-4-623-17114-4431-695
Free Cash Flow59496352-79114131137182-205-55-155

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days21520818219416918617716015348105112
Inventory Days3123683052912843133012882426145187
Days Payable1201379111811412311111811352140185
Cash Conversion Cycle4074393963673393753673302822110114
Working Capital Days141-26-97-492172482532532342115156
ROCE %12244577132035

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Sep 2026
Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters424242424241413939434343
FIIs0.310.261.270.650.463.074.271514141111
DIIs198.030.940.940.940.910.910.680.6800.170.15
Public395056565755544546434646
No. of Shareholders24,63322,43925,46128,88328,75228,11728,70943,78042,12139,22240,88142,112

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +244.6% (₹104.73 → ₹360.90)Brick size ₹23.72 (fixed)Bricks 14
₹100₹200₹300₹400₹361Jun '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹360.90 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

company capacity utilisation %

70.00pct

2026-06-30

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-424inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

73.80cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Ind-Swift Laboratories Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Chemical intermediates / KSMs for API synthesis
  • Erythromycin A (Clarithromycin synthesis precursor)
  • Packaging materials (blister PVC/Al foil, glass vials, HDPE bottles)
  • Pharmaceutical excipients (MCC, lactose, starch, talc)
  • Solvents (DMF, NMP, methanol, acetone, ethanol, toluene)

Buys from

Sells to

  • Ind-Swift Limited (group formulations arm) · APIs & intermediates supplied to group formulation business (group collaboration)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE915B01019

Plants

  • Derabassi API complex
  • Global Business Unit (GBU) / Export Unit, Derabassi
  • HPAPI / Oncology API facility, Derabassi
  • R&D Centre, Mohali
  • Samba Unit

News impact

Big market events that reach Ind-Swift Laboratories Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

20 Sep 2011unspecified₹1
16 Sep 2010unspecified₹1

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
29 May 2026HRTI PRIVATE LIMITEDBUY6,70,635₹155.10
29 May 2026HRTI PRIVATE LIMITEDSELL2,02,663₹153.04
17 Apr 2026HCP INVESTMENTSSELL48,00,000₹134.18
17 Apr 2026F3 ADVISORS PRIVATE LIMITEDSELL8,35,425₹133.17
17 Apr 2026NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONEBUY8,03,387₹138.07
17 Apr 2026MANSI SHARE AND STOCK BROKING PRIVATE LIMITEDBUY7,98,784₹132.66
17 Apr 2026F3 ADVISORS PRIVATE LIMITEDBUY7,02,431₹133.25
17 Apr 2026MANSI SHARE AND STOCK BROKING PRIVATE LIMITEDSELL6,96,283₹136.17
17 Apr 2026SHARE INDIA SECURITIES LIMITEDBUY6,89,971₹134.28
17 Apr 2026SHARE INDIA SECURITIES LIMITEDSELL5,81,829₹135.53

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
28 Sep 2026PARDEEP VERMA · KMPSELL6,1400.25

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.